Search clinical trials for: ABO2109 Injection;Toripalimab

Total 10000 results

1
2
3
4
5
6
7
8
9
10
...
199
200
›

Suzhou Abogen Biosciences Co., Ltd.
The First Affiliated Hospital of Soochow University

Not yet recruiting

An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid Tumors

Solid Tumors
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd

Recruiting

Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid Tumors

Solid Tumor, Adult

China
Ruijin Hospital
Suzhou Abogen Biosciences Co., Ltd.

Recruiting

Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors

Pancreatic Neoplasms | Other Solid Tumors

China
Suzhou Abogen Biosciences Co., Ltd.
Abogen Biosciences (Shanghai) Co., Ltd

Recruiting

Study of ABO2102 in KRAS-Mutated Solid Tumors

Advanced / Metastatic Solid Tumor

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Trial of LBL-024 Monotherapy, LBL-024 Combined With LBL-007 or Toripalimab in Patients With Advanced Melanoma

Advanced Melanoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors

Advanced Malignant Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Breast Cancer | Non Small Cell Lung Cancer | Advanced Solid Tumors

China
Ruijin Hospital

Recruiting

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)

B-cell Non-Hodgkin Lymphoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Ruijin Hospital
Abogen Life Sciences (Shanghai) Co., Ltd.

Recruiting

A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Refractory Autoimmune Diseases

Autoimmune Diseases

China
Ascentage Pharma Group Inc.

Terminated

Dose-escalation Study of APG-1387 and Toripalimab in Solid Tumors

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Urothelial Carcinoma

China
Nanjing Immunophage Biotech Co., Ltd

Not yet recruiting

IPG7236 Combined With Toripalimab in Participants With Advanced Solid Tumors

Advanced Solid Tumor

China
Nanjing Leads Biolabs Co.,Ltd

Completed

A Phase Ib/II Clinical Study of LBL-007 in Combination With Toripalimab in Treatment of Advanced Malignant Tumors

Advanced Malignant Tumors

China
Shanghai Pushi Medical Science Co. Ltd

Recruiting

Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002

Advanced Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Limited-stage Small Cell Lung Cancer (LS-SCLC)

China, France, United States, Spain, Taiwan, Korea, Republic of, Turkey, Italy, Netherlands, Georgia, Germany, Belgium, Poland, Romania
Shanghai Junshi Bioscience Co., Ltd.

Not yet recruiting

Intensive Medicines Monitoring Study of Toripalimab Monoclonal Injection (Tuoyi) .

Melanoma | Breast Cancer | Lung Cance

China
RemeGen Co., Ltd.

Recruiting

A Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors

Advanced Solid Tumor

China
Hebei Medical University Fourth Hospital

Not yet recruiting

Toripalimab Adjuvant Therapy in Subjects With Resected Esophageal Squamous Cell Carcinoma Who Achieved Pathological Complete Response (pCR)

Esophageal Squamous Cell Carcinoma Stage II | Esophageal Squamous Cell Carcinoma Stage III

China
Shanghai Junshi Bioscience Co., Ltd.
Sponsor GmbH

Terminated

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Liver Cancer, Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma, Cervical Cancer, MSI-H Colorectal Cancer

China
Chipscreen Biosciences, Ltd.

Not yet recruiting

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Metastatic Pancreatic Ductal Adenocarcinoma

China
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer

China
Nanjing Leads Biolabs Co.,Ltd
The First Affiliated Hospital with Nanjing Medical University

Recruiting

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
First Affiliated Hospital of Guangxi Medical University

Not yet recruiting

A Prospective, Multicenter, Open-label, Single-arm Phase II Clinical Study Evaluating the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With the PraG Strategy for the Treatment of Soft Tissue Sarcoma

Soft Tissue Sarcoma (STS)

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer

China
LaNova Medicines Limited

Recruiting

LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma

Locally Advanced or Metastatic GC and GCJ Adenocarcinoma

China
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Efficacy and Safety of TQB2618 Injection Combined With Toripalimab Injection in Patients With Advanced Melanoma

Melanoma

China
NingBo Junyan Hongshi Biosciences Co., Ltd

Not yet recruiting

JS107 in Combination With Toripalimab and Chemotherapy for the Treatment of CLDN18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma

Gastric Adenocarcinoma

China
Sun Yat-sen University

Recruiting

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody Improve Mixed Chimerism (HLH)

PD-1 Antibody | Mixed Chimerism

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Recruiting

Toripalimab Combined With Donafenib in the Treatment of Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma

China
Wan He

Recruiting

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC)

Stomach Neoplasms

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Sun Yat-sen University
Fujian Cancer Hospital; Hunan Cancer Hospital; The University of Hong Kong-Shenzhen... and other collaborators

Recruiting

Toripalimab Vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma (Navigation)

Nasopharyngeal Carcinoma (NPC)

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Third Military Medical University

Recruiting

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Lung Cancer | SCLC, Extensive Stage

China
Beijing Friendship Hospital

Not yet recruiting

PD-1 Antibody for Reactive EBV After BMT

Transplant | EBV Infection | PD-1

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKI

Non-small Cell Lung Cancer

China
Lyvgen Biopharma Holdings Limited

Active, not recruiting

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

Head and Neck Squamous Cell Carcinoma

China
Hubei Cancer Hospital

Completed

Toripalimab Combined With Anlotinib and SBRT in Patients With Untreated Brain Metastases of Driven Gene-negative NSCLC

NSCLC

China
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
Eye & ENT Hospital of Fudan University
Changhai Hospital; Shanghai Zhongshan Hospital; Fujian Medical University Union... and other collaborators

Recruiting

Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC

Recurrent Nasopharyngeal Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zenith Institute of Medical Sciences, Guangzhou

Not yet recruiting

Safety and Tolerability of a mRNA Vaccine Encoding Tumor-Specific Circular RNA Antigens in Combination With Anti-PD-1 Monoclonal Antibody in Patients With Advanced Solid Tumors

Solid Tumor
Fudan University

Not yet recruiting

Real-World Study of Toripalimab in Extensive-Stage Small Cell Lung Cancer

SCLC, Extensive Stage | Toripalimab
Tianjin Medical University Cancer Institute and...

Not yet recruiting

A Phase II Study of Toripalimab Plus Chemotherapy and Low-Dose Radiotherapy for Neoadjuvant Therapy-Refractory Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma (ESCC)
Fujian Cancer Hospital

Not yet recruiting

Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma

Locally Advanced Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study

Esophageal Squamous Cell Carcinoma (ESCC)
RemeGen Co., Ltd.

Recruiting

DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

Breast Cancer

China

1
2
3
4
5
6
7
8
9
10
...
199
200
›

Subscribe